The startup has developed an AI-driven platform that enhances breast cancer screening and diagnosis by improving patient compliance and provider accuracy through advanced data analytics and patient engagement tools. This platform addresses inefficiencies in the cancer screening process, ultimately leading to better clinical outcomes and quality of care.
Funding
$92.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Breast cancer screening and diagnosis face challenges in ensuring consistent and accurate assessments, leading to potential delays in detection and suboptimal patient outcomes. Manual processes and variability in radiologist interpretations can contribute to inconsistencies in breast density assessment and risk stratification.
Solution
Whiterabbit.ai offers AI-driven software solutions, WRDensity and WRRisk, designed to improve the mammography screening process. WRDensity assists radiologists in interpreting breast density, promoting uniformity in assessments across practices by leveraging a deep learning model trained on over 600,000 images. WRRisk is a clinical decision support tool that integrates with PACS to display risk scores and WRDensity data, enabling personalized risk assessments. The platform aims to enhance diagnostic accuracy, streamline workflows, and ultimately facilitate earlier detection of breast cancer.
Target Audience
The primary target audience includes radiologists, radiology practices, and healthcare providers involved in breast cancer screening and risk assessment.
Features
- WRDensity: AI-driven breast density software for consistent interpretation of mammograms.
- WRDensity: Trained on over 600,000 images from the Mallinckrodt Institute of Radiology.
- WRDensity: RIS/PACS compatible for seamless integration into existing workflows.
- WRDensity: Longitudinal study shows more consistent assessments compared to radiologists.
- WRRisk: Clinical decision support software for breast cancer risk assessment.
- WRRisk: PACS integrated to display risk scores and WRDensity data.
- WRRisk: Facilitates personalized determination of breast cancer risk.
- Both products are designed to improve patient compliance with screening guidelines.